Dr. Reddy’s Files Q4 FY26 Audited Results Presentation with Exchanges
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dr Reddy’s Laboratories ( (RDY) ) has issued an update.
On May 12, 2026, Dr. Reddy’s Laboratories filed a Form 6-K with the U.S. Securities and Exchange Commission, furnishing an intimation to stock exchanges about its audited financial results for the quarter and financial year ended March 31, 2026. The company informed the National Stock Exchange of India, BSE, the New York Stock Exchange and NSE IFSC that a presentation on these Q4 FY26 and full-year audited results has been shared for investor information and records, underscoring ongoing transparency and compliance with SEBI’s disclosure requirements for listed entities.
While the filing itself does not disclose the financial figures, it confirms that detailed audited results and accompanying materials are now formally available to the market as of May 12, 2026. This step ensures shareholders and other stakeholders in India and overseas have access to standardized, regulator-compliant information on Dr. Reddy’s recent financial performance, which can influence investment decisions and shape perceptions of the company’s operational momentum in the just-ended fiscal year.
The most recent analyst rating on (RDY) stock is a Buy with a $16.90 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company headquartered in Hyderabad, Telangana. The company develops, manufactures and markets a wide range of generic medicines, active pharmaceutical ingredients and proprietary products for regulated markets including India, the U.S. and other international geographies.
Average Trading Volume: 2,375,381
Technical Sentiment Signal: Hold
Current Market Cap: $11.29B
Find detailed analytics on RDY stock on TipRanks’ Stock Analysis page.
